


Supplementary Figure 11



Supplementary Figure S11. The removal of mutant TP53 does not cause a competitive growth disadvantage in human cancer cell lines in vitro

A, B. The indicated control mutant TP53 expressing human cancer cell lines, labeled with BFP, and their mutant TP53 deleted derivatives, labeled with GFP, were seeded each at 30K into 24-well plates at a 50/50 ratio and were left **(A)** untreated or **(B)** treated with the indicated doses of etoposide. The medium and etoposide were refreshed every 3 days when the percentages of viable GFP positive and viable BFP positive cancer cells were examined by flow cytometry. Data are expressed as mean \pm SEM of the percentages of viable cancer cells of a given type at a given time in culture, from three independent experiments.